ARTICLE | Company News
Cardinal Health, Microphage sales and marketing update
October 17, 2011 7:00 AM UTC
MicroPhage granted Cardinal Health exclusive U.S. and Canadian commercialization rights to KeyPath MRSA/MSSA Blood Culture Test and other undisclosed products in development to detect Staphylococcus aureus. Cardinal will fund development and commercialization of the products. Terms were not disclosed. ...